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Sickle cell disease (SCD) affects approximately
72,000 people in the United States (approximately 1 in
500 African Americans and 1 in 1000 to 1400
Hispanics).1 During the past three decades, the
survival of patients with SCD has improved
significantly, partly because transfusion therapy2,3 has
played a role as a disease-modifying strategy for 
several manifestations of the disease, including acute
chest syndrome,acute intrahepatic sequestration,acute
multiorgan failure syndrome, acute splenic sequestra-
tion, acute symptomatic anemia, aplastic crisis,
bacterial and malarial infections, chronic organ failure,
complicated pregnancy, eye surgery (e.g., scleral
buckle procedure), frequent pain episodes, priapism,
primary and secondary prevention or treatment of
stroke, and surgery requiring general anesthesia.
Depending on clinical circumstances, patients with
one or more of the aforementioned manifestations may
receive simple or exchange RBC transfusions that are
administered episodically or chronically. However,
each transfusion of a unit of RBCs poses a risk of RBC
antigen alloimmunization. Studies show that 25
percent or more of chronically transfused SCD patients
may experience this complication unless precautions
are taken.4 When alloimmunization occurs, the most
common clinically significant antibodies to develop in
transfused SCD patients include antibodies to Rh and
Kell antigens.5–8
It is preferable to avoid alloimmunization to RBC
antigens because this complication makes obtaining
compatible units for future transfusions difficult and
places the patient at risk for development of hemolytic
transfusion reactions, the symptoms of which can
mimic or trigger serious complications of SCD. In
addition, hemolytic transfusion reactions can be
serious and potentially life-threatening complications
in their own right. Studies have shown that the
transfusion of ABO- and D-compatible donor RBCs that
lack C, E, or K when the same antigens are absent from
the recipient’s RBCs can reduce the rate of alloimmuni-
zation in patients with SCD as well as the occurrence
of hemolytic transfusion reactions.
According to a National Institutes of Health (NIH)
publication3 (pages 155–158) the antigenic phenotype of the
RBCs (at least the common antigens belonging to ABO,
Rh, Kell, Duffy, Kidd, Lewis, Lutheran, P, and MNS)
should be determined in all patients older than 6
months. A permanent record of the phenotype results
should be maintained in the blood bank to optimize
matching and a copy of the record should be given to
the patient or family. Furthermore, limited matching of
donor RBCs for E, C, and K is usually performed, unless
patients have antibodies. The transfusion of pheno-
typically matched RBCs may be accomplished by
typing the RBCs of the patient before transfusion, if not
previously performed, for Rh and Kell, in particular E,
C, and K and performing more extensive matching for
antigens in systems such as Duffy, Kidd, and MNS for
those patients who are already alloimmunized. Donor
RBCs lacking the antigens that the patient’s RBCs lack
would then be selected for transfusion.
Although NIH publication 02-2117 was not the
result of a formalized consensus process, it does
represent the efforts of those who have dedicated their
professional careers to the care of individuals with
SCD. In spite of this publication, transfusion practices
in SCD remain disparate in the United States, as
illustrated by two recent national surveys.
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Afenyi-Annan and Brecher surveyed 50 academic
medical centers to determine the extent of the use of
phenotype-matched donor RBCs in the transfusion of
patients with SCD.9 Of 37 academic centers that
responded to a questionnaire, 27 (73%) reported that
they provide antigen-matched donor RBCs. Although
the most common antigens matched were C, E, and K
(24 of the 27 sites or 89%), there were multiple
variances among those 27 centers as to which antigens
were selected for phenotype matching. The authors
concluded that, despite a common approach by some
of the academic centers, there was no single standard
of care with regard to RBC component selection.
A survey by the College of American Pathologists
(CAP) examined 1182 labs in North America to
determine the extent of RBC antigen testing of
nonalloimmunized patients with SCD as well as the use
of phenotype-matched donor RBCs in the transfusion
of these patients.10 The CAP survey, unlike the one by
Afenyi-Annan and Brecher, did not specifically target
academic medical centers. The CAP survey results
indicated that approximately 63 percent of North
American laboratories did not routinely phenotype
patients with SCD for antigens other than ABO and D.
Of the 37 percent of the laboratories that did perform
additional antigen testing beyond ABO and D, only 75
percent actually selected phenotype-matched RBCs for
patients with SCD. On the other hand,more than three-
quarters of the respondent laboratories reported that
for patients with SCD they use RBCs that are leukocyte
reduced and nearly two-thirds of these laboratories
reported that they use RBCs that test negative in a
sickle cell screening test. The authors of the CAP
survey concluded that the majority of North American
hospitals do not determine the RBC phenotype of
nonalloimmunized patients with SCD (beyond ABO
and D) and the laboratories that do perform RBC
antigen testing of these patients beyond ABO and D
most commonly match for C, E, and K when
phenotype-similar RBCs are transfused.
The authors in this issue of Immunohematology
describe various transfusion management protocols
used for patients with SCD for whom they care in their
institutions: those designated as comprehensive sickle
cell centers and others around the country. All of these
centers actively treat patients with SCD. Given the lack
of consensus in the United States regarding the need to
perform RBC phenotyping of patients with SCD, and
the use of phenotypically-matched donor RBCs for
their transfusions, it will be interesting to read the
articles that follow with regard to alloimmunization
and to the use of leukocyte-reduced, irradiated, storage
duration limited, and HbS negative RBC components.
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